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Abstract 25 
Highly Pathogenic Avian Influenza Viruses (HPAIVs) cause huge economic losses in the 26 
poultry industry because of high mortality rate in infected flocks and trade restrictions. 27 
Protective antibodies, directed mainly against hemagglutinin (HA), are the primary means of 28 
protection against influenza outbreaks. A recombinant DNA vaccine based on the sequence of 29 
H5 HA from the H5N1/A/swan/Poland/305-135V08/2006 strain of HPAIV was prepared. 30 
Sequence manipulation included deletion of the proteolytic cleavage site to improve protein 31 
stability, codon usage optimization to improve translation and stability of RNA in host cells, 32 
and cloning into a commercially available vector to enable expression in animal cells. Naked 33 
plasmid DNA was complexed with a liposomal carrier and the immunization followed the 34 
prime-boost strategy. The immunogenic potential of the DNA vaccine was first proved in 35 
broilers in near-to-field conditions resembling a commercial farm. Next, the protective 36 
activity of the vaccine was confirmed in SPF layer-type chickens. Experimental infections 37 
(challenge experiments) indicated that 100% of vaccinated chickens were protected against 38 
H5N1 of the same clade and that 70% of them were protected against H5N1 influenza virus of 39 
a different clade. Moreover, the DNA vaccine significantly limited (or even eliminated) 40 
transmission of the virus to contact control chickens. Two intramuscular doses of DNA 41 
vaccine encoding H5 HA induced a strong protective response in immunized chicken. The 42 
effective protection lasted for a minimum 8 weeks after the second dose of the vaccine and 43 
was not limited to the homologous H5N1 virus. In addition, the vaccine reduced shedding of 44 
the virus. 45 
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1. Introduction  50 
DNA vaccines are new-generation vaccines offering many advantages over 51 
conventional ones (Liu, 2011). They are relatively simple, easy and fast to produce, generate 52 
low costs in storage and transport, and are more stable than protein formulations. Numerous 53 
data show the effectiveness of experimental DNA immunizations against various viral, 54 
bacterial, parasitic and cancer diseases. However, only a few veterinary products have been 55 
registered to date in the USA and Canada, and despite several clinical trials, no human DNA 56 
vaccine is available (Ferraro et al., 2011; Kutzler and Weiner, 2008). Various experimental 57 
DNA vaccines have been tested in poultry (Oshop et al., 2002). The high potential of DNA 58 
immunization, particularly in cases requiring a rapid response to an influenza pandemic have 59 
led to the development of this technology and  increase of report on DNA vaccines for 60 
chickens against influenza (Chen et al., 2001; Jiang et al., 2007; Kodihalli et al., 2000; Lee et 61 
al., 2006; Lim et al., 2012; Rao et al., 2008; Shan et al., 2011; Suarez and Schultz-Cherry, 62 
2000)  63 
The influenza virion has several structural and non-structural antigens, namely 64 
hemagglutinin (HA), neuraminidase (NA), capsid protein (M1), ion channel protein (M2), 65 
nucleoprotein (NP) and the components of the viral polymerase PA, PB1 and PB2 (Steinhauer 66 
and Skehel, 2002). Although detectable antibody responses are observed against many viral 67 
proteins, the major determinants for a protective response are antibodies produced against 68 
surface glycoprotein HA, the most prominent antigen of the virus (see the review (Skehel and 69 
Wiley, 2000) and references therein). HA is synthesized as a precursor polypeptide H0 and is 70 
then cleaved into subunits H1 and H2. The HA cleavage site is the main determinant of the 71 
pathogenicity of influenza viruses. In low-pathogenic avian influenza viruses (LPAIVs) the 72 
cleavage site can be limited to a single arginine residue recognized by extracellular trypsin-73 
like proteases, while in high-pathogenic viruses (HPAIV) the H0 precursor contains a 74 
sequence that can be recognized by proteases present in nearly all cell types, which facilitates 75 
systemic spread of the virus (Skehel and Wiley, 2000; Steinhauer and Skehel, 2002). 76 
In the EU, permission to vaccinate poultry against H5N1 HPAI can be granted after 77 
the fulfillment of strict requirements laid down in the EU Directive for the Control of AI 78 
(Council Directive 2005/94/EC). The Directive is concerned with the high risk of a “silent 79 
spread” of the virus due to incomplete protection at a flock level, leading to the impossibility 80 
of differentiating the infected from the vaccinated individuals in case of usage of inactivated 81 
vaccines. Therefore, considering the needs of the DIVA (Differentiating Infected from 82 
Vaccinated Animals) strategy, there is a great demand for new-generation vaccines (Capua, 83 
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2007; European_Commission, 2006; Savill et al., 2006). It is strongly recommended by the 84 
OIE and the EU that preventive and emergency vaccination should be an additional method of 85 
controlling and fighting the virus in case of disease outbreak, by protecting  valuable flocks 86 
and reducing the spread of virus in restriction and buffer zones.  87 
The H5N1 strain of HPAIV which is the object of our studies and caused the Asian 88 
epidemic in 2003 was first identified in domestic gees in China in 1996 (Xu et al., 1999). 89 
After several years of spreading and genetic diverging in South Eastern Asia, some strains 90 
have crossed the Russian border and reached the Middle East and Europe (Cattoli et al., 91 
2009). Several local outbreaks appeared in almost all European countries, both on poultry 92 
farms and among wild birds. In March 2006, the first disease outbreak was reported in Poland 93 
in mute swans (Minta et al., 2007; Śmietanka et al., 2008). Despite the high standards of food 94 
and animal trade in the EU due to the intense human and animal movement the risk of virus 95 
re-emergence is high. In this study the immunization experiments were conducted with 96 
common broiler type chicken grown in a biologically secure poultry-house. The duration of 97 
the immunization experiments was 6 weeks, because such is the length of broilers’ life. Two 98 
intramuscular doses of DNA vaccine were sufficient to stimulate the anti-HA response in sera 99 
of immunized chickens. The second series of experiments involved challenge with HPAI 100 
H5N1 viruses and were conducted in a P3 laboratory using SPF chickens of laying type, 101 
which allowed the time of the experiments to be extended to 8-13 weeks in order to test for 102 
the long-term protection. The challenge experiments indicated a high protective potential of 103 
the tested DNA vaccine. The immunized SPF chickens were protected in 100% against H5N1 104 
virus from a homologous clade (clade 2.2) and in 80% against the H5N1 virus from a 105 
heterologous clade (clade 1). 106 
2. Materials and methods 107 
2.1. Plasmids and vaccine design 108 
Based on the predicted amino acid sequence of HA from H5N1 A/swan/Poland/305-109 
135V08/2006 strain of HPAIV (EpiFluDatabase [http://platform.gisaid.org]; Accession No. 110 
EPI156789), a synthetic gene optimized to the domestic chicken codon bias and containing 111 
deletion of the proteolytic cleavage site (from Arg-341 to Arg-346) was designed (GenBank 112 
Accession No. KC172926). Two variants of the DNA vaccine were prepared: (i) long, codon-113 
optimized HA (aa 1-568) with the original N-terminal signal peptide of 16 amino acids 114 
(aa 1-16) and a deletion of the proteolytic cleavage site RRRKKR (Δ341-346) and (ii) short, 115 
codon-optimized HA, containing only aa 17-340 (only H1 subunit, without signal peptide). 116 
The non-optimal codons in the native HA gene sequence were replaced by codons optimized 117 
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to chicken codon usage and the sequence was also checked for the absence of cryptic splice 118 
sites (commercial service by GenScript USA Inc.). The inserts were cloned into the pCI 119 
(Promega) between immediate-early enhancer/promoter from Cytomegalovirus (CMV) and a 120 
terminator/polyadenylation signal from SV40. Plasmid DNA was purified using NoEndo 121 
JETSTAR Plasmid Kit (Genomed, Germany) and suspended in PBS pH 7.4, and the 122 
appropriate amount of DNA (62-250 µg) was mixed with the Lipofectin transfection reagent 123 
(Life Technologies, USA) as recommended by the manufacturer. In each trial the same ratio 124 
of DNA amount (w):Lipofectin (v), 6:1 was used. The volume of one dose of vaccine was 160 125 
µl. 126 
2.2. Influenza viruses and stock preparation 127 
Table 1 lists the used influenza viruses. The HPAIVs were propagated in the allantoic cavities 128 
of embryonated chicken eggs (Valo-Biomedia, Germany) in biosafety level 3 conditions of 129 
the National Veterinary Research Institute (Pulawy, Poland) and stored in aliquots at -70°C 130 
(for challenge purpose) or inactivated with 0.1% formaldehyde (Sigma–Aldrich, MO, USA) 131 
for 2 h at 37°C (for hemagglutination inhibition test). The LPAIVs were either purchased or 132 
kindly provided by others. The viral stocks stored at -70°C were titrated before use. 133 
2.3. Immunization and challenge experiments 134 
Broilers (Ross 308) were housed in poultry-house in cages, in standard commercial conditions 135 
including temperature, photoperiod, litter and fodder. Five independent immunizations of 136 
broilers were conducted. Depending on the experiment, animals (7-15 per group) were 137 
immunized subcutaneously in the neck or intramuscularly in the breast muscle with the 138 
indicated amount of DNA complexed with Lipofectin.  Blood was collected from the wing 139 
veins, allowed to coagulate, and centrifuged. The collected sera were kept at -20°C.  140 
Specific pathogen free (SPF) White Leghorn chickens, housed in a biosafety level 3 141 
containment of the National Veterinary Research Institute, Pulawy, were immunized 142 
intramuscularly twice (using 1-ml syringe with 0.5x 1.6 mm needle) with the DNA vaccine 143 
containing 125 µg of plasmid DNA complexed with Lipofectin. Prior to the challenge, the 144 
chickens were placed in separate isolators (Montair Andersen B.V., Holland) equipped with 145 
HEPA filters. Three challenge experiments were performed. The immunized chickens (10 146 
birds/group in Experiments 1 and 3, and 5 birds in Experiment 2) as well as control 147 
(untreated, fully susceptible chickens, 2-5/group) were inoculated occulonasally with 10
6
 50% 148 
egg infectious dose (EID50) of the respective virus in the volume of 100 µl (50 µl into the 149 
nares and 50 µl into the eye per bird). Approximately 24 h after inoculation, 6-week-old 150 
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contact SPF chickens (1 or 2 per group) were placed in the same isolators as the vaccinated 151 
chickens to monitor virus transmission. Other details are shown in Table 2. 152 
2.4. Ethic statements 153 
The experiments were approved by the Second Local Ethical Committee for Animal 154 
Experiments at the Medical University of Warsaw, Permit Number 17/2009 (broilers) or the 155 
Second Local Ethical Committee for Animal Experiments at the University of Life Sciences 156 
in Lublin, Permit Number 26/2012 (SPF chickens). All efforts were made to minimize 157 
suffering. The chickens were monitored twice a day (morning and afternoon), including 158 
weekends. The immunized chickens were sacrificed (humanely euthanized by decapitation) 159 
about 3 weeks after the final immunization (about 6 weeks after hatching).  160 
2.5. ELISA 161 
The 96-well polystyrene plates (Nunc, Denmark) were coated overnight at 4°C with 300 ng of 162 
HA antigen (A/swan/Poland/305-135V08/2006 (H5N1)) produced in a baculovirus system 163 
(Oxford Expression Technologies, UK). Bound IgY were detected using goat anti-chicken 164 
IgY (Fc-specific)-HRP (Pierce/Thermo Scientific, IL, USA) antibodies. Results were 165 
analyzed using the STATISTICA program (StatSoft, Poland).  166 
2.6. Hemagglutinin Inhibition 167 
The HI test was conducted according to the standard procedure ([O.I.E.] World Organization 168 
for Animal Health, 2012). Shortly, the collected sera (25 µl of sera in serial two-fold 169 
dilutions) were incubated for 25 min in a titration plate with four HA units of the inactivated 170 
antigen. Next, a suspension of 1% hen erythrocytes was added and incubated for 30 min. The 171 
HI titer was determined as the reciprocal of the highest dilution in which hemagglutination 172 
was inhibited. Sera from Trials 1-5 were tested using the heterologous strain H5N2 173 
A/chicken/Belgium/150/1999 (GD Deventer, Netherlands). Sera from the Challenge 174 
Experiments 1-3 were tested with a much broader range of antigens (see Table 1). 175 
2.7. Determination of viral titers 176 
The level of viral RNA in samples from challenged chickens was assayed by quantitative real 177 
time RT-PCR/M using RNA isolated with the RNeasy Mini Kit (Qiagen, Hilden, Germany) 178 
as described (Spackman et al., 2002). Oligonucleotides M-25 (5’-AGATGAGTCTTCTAA 179 
CCGAGGTCG-3’) and M-124 (5’-TGCAAAAACATC TTCAAGTCTCT-3’) were used as 180 
primers and M-64 (5’-FAM-TCAGGCCCCCTC AAAGCCGA-TAMRA-3’) served as a 181 
probe. Quantitative standards of RNA extracted from 10-fold dilutions of a titrated virus 182 
homologous to the challenge strain were used to convert and express the QRT-PCR Ct values 183 
as equivalent EID50 (eqEID50) per milliliter of swab fluid from oropharyngea and cloaca. 184 
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3. Results 185 
3.1. Immune responses of chickens to DNA vaccines 186 
Five independent immunization experiments with slightly different time schedule of priming, 187 
boosting and blood collection were conducted in experimental farm conditions (Table 2, 188 
Figure 1). The duration of each experiment did not exceed 6 weeks, the life span of broilers. 189 
In the initial experiment (Trial 1) we focused on the evaluation of the immunogenic potential 190 
of two variants (short and long) of the DNA vaccine. The plasmid containing the long 191 
sequence appeared to be better vaccine candidate than the one with the short (H1) sequence 192 
(Figure 1A), therefore we concentrated only on the long DNA vaccine in further experiments. 193 
The minimal amount of plasmid DNA inducing satisfactory response by subcutaneous route 194 
was assessed in the next experiment (Trial 2) as 125 µg (Figure 1B). When two high doses of 195 
250 µg DNA were administered without Lipofectin the anti-HA response was significantly 196 
lower than the response to two doses of 250 µg or two doses of 125 µg administered with the 197 
carrier.  198 
Subsequent trials (Trials 3-5) (i) allowed us to choose the intramuscular route as superior to 199 
the subcutaneous, (ii) confirmed that the intramuscularly injected dose of 125 µg of the long 200 
variant of the DNA vaccine is sufficient to induce anti-HA humoral response in 100% of 201 
chicken, and (iii) demonstrated that two doses of the vaccine are necessary to induce 202 
antibodies capable of hemagglutination inhibition (Figure 1C). The results of all trials 203 
consistently indicated that two weeks after priming (just before boosting) anti-HA antibodies 204 
could be detected in sera. However, the second dose of the vaccine (boosting) resulted in a 205 
strong increase of anti-HA antibody titers in most groups (as detected 3 weeks after the boost) 206 
and in increase of hemagglutinin inhibition (HI) activity (Figure 1 and Supplementary Figure 207 
1). Generally, irrespective of the experimental group, no HI activity was detected in sera with 208 
low titers of anti-HA antibodies.  209 
3.2. Dynamics of serological response 210 
The previously optimized immunization schedule (intramuscular route, 125-µg dose, 211 
prime/boost on days 7/21) was applied to SPF chickens. Then, on day 42 (Experiment 1 and 212 
3) or 77 (Experiment 2) chickens were challenged with either H5N1 HPAIV from clade 2.2 213 
(Experiments 1-2) or  H5N1 HPAIV from clade 1 (Experiment 3). The HI response in sera of 214 
immunized and challenged chickens is shown in Figure 2 and Supplementary Figure 2. 215 
Consistently, the best HI response was against an antigen homologous to the one encoded by 216 
the DNA vaccine. At 3 weeks post booster (wpb) (challenge day in Experiment 1 and 217 
Experiment 3) all birds were HI-positive with the following values of Geometric Mean Titers 218 
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(GMT): 169 (Experiment 1), 97 (Experiment 2) and 111 (Experiment 3). However, only 60-219 
80% of birds tested on the challenge day (3 wpb or 8 wpb) were found positive with antigen 220 
from heterologous and antigenically distant clade and the percentage of seropositive chickens 221 
never reached 100%. The strong elevation of HI antibody was always observed 2 weeks after 222 
challenge. 223 
3.3. Protection against challenge and viral shedding 224 
The survival ratio after the challenge is shown in Figure 3, while the amount of viral RNA in 225 
swabs collected from the immunized/infected and the contact groups is summarized in Table 226 
3. All control chickens (non-immunized, challenged) died by 3 dpi and large amounts of the 227 
virus (usually > 5 log10 EID50 per ml swab fluid) were found. In Experiment 1 (challenge with 228 
the homologous virus 3 weeks after the boosting), no clinical signs or mortality were 229 
observed in immunized chickens or contact birds (Figure 3A). The small amount of the virus 230 
(up to 3 log10 EID50) was detected in oropharyngeal swabs of single birds tested at 3 dpi and 231 
14 dpi. This seems, however, to be probably below the infecting dose, which is reflected in 232 
the survival of the contact birds. In Experiment 2 (challenge with the homologous virus 8 233 
weeks after boosting), the vaccinated and challenged chickens remained clinically healthy, but 234 
the contact bird developed clinical symptoms and died 7 days after the vaccinated birds had 235 
been challenged (Figure 3B). The virus was found at 3 dpi in the oropharyngeal swabs 236 
collected from 2 immunized birds (amount of RNA equivalent to 3.3 log10 EID50) while in 237 
dead contact chicken a the viral RNA was present both in respiratory and digestive tracts 238 
(quantity corresponding to 6.2 and 4.6 log10 EID50, respectively). Regarding Experiment 3 239 
(challenge with the virus from the heterologous clade 3 weeks after boosting), three 240 
immunized and infected birds died on days 5, 10 and 13, but viral RNA was never detected in 241 
swabs taken from the immunized chicken found dead at 13 dpi. Both contact chickens were 242 
found dead 2 days after they had been placed in the isolator with the challenged birds (Figure 243 
3C). The vaccinated and challenged chickens shed the virus up to 10 dpi with the peak at 3 244 
dpi (seven birds, amount of RNA equivalent to 2.4-5.8 log10 EID50, see Table 3).  245 
 246 
4. Discussion 247 
This work focused on testing the DNA vaccine effective in chickens that can be used in case 248 
of influenza outbreak. Comparison of two immunization routes resulted in choosing the 249 
intramuscular injection as better and more reliable than the subcutaneous one (Figure 1C). 250 
This route of injection was also more convenient for the personnel and, in our evaluation, 251 
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better tolerated by birds. In other reports this route was also often used for DNA 252 
immunizations with HA-encoding plasmids (Jalilian et al., 2010; Jiang et al., 2007; Lim et al., 253 
2012; Oveissi et al., 2010) and gave good results; however, other, more sophisticated methods 254 
like gene gun (Kodihalli et al., 2000), electroporation (Shan et al., 2011) or needle free jet 255 
injector (Rao et al., 2008) were sometimes found more effective. We have also established the 256 
minimal dose inducing the satisfactory response as 125 µg. In other works a very broad range 257 
of doses was tested and showed to be effective. Usually around 10-200 µg ensured high or 258 
average level of response and protection (Jalilian et al., 2010; Jiang et al., 2007; Kodihalli et 259 
al., 2000; Lim et al., 2012; Oveissi et al., 2010; Rao et al., 2008; Shan et al., 2011).  260 
The reported here immunization protocol, initially optimized in broilers in experimental farm 261 
conditions, was used in three challenge experiments with H5N1 HPAIVs using SPF White 262 
Leghorn chickens kept in a biosafety level 3 laboratory. Two HPAIV strains were used for 263 
challenge. The first was A/turkey/Poland/35/07 from clade 2.2 that reached Europe at the end 264 
of the year 2005 and circulated for several months in European countries causing small local 265 
outbreaks. The second was A/crested eagle/Belgium/01/04 from the distinct clade 1 which 266 
was circulating in southern Asia for several years and was once found at the Brussels airport 267 
in smuggled birds (Van Borm et al., 2005). The mortality rate of the challenged animals was 268 
monitored, virus shedding and transmission were tested, and the dynamics of serological 269 
response (HI test) followed. All immunized birds were protected against the homologous 270 
virus used in challenge Experiments 1 and 2. Transmission of the virus was absent in the 271 
challenge Experiment 1 (infection at 3 wpb), while it was observed in Experiment 2 (infection 272 
at 8 wpb). As a result, a control contact chicken died 7 days after inoculation. It should be 273 
pointed out that shedding of the virus was mild and infection in the contact chicken developed 274 
with a delay of several days. Of the ten chickens vaccinated in Experiment 3 (challenge with 275 
heterologous H5N1 HPAIV) two died and had moderate to high levels of viral RNA in 276 
oropharyngeal and cloacal swabs, as well as in the lung, brain, kidney and spleen samples. 277 
The third chicken died also at the last day of observation. However, it was clinically healthy 278 
throughout the experiment and no virus RNA was detected at any time; therefore, we assumed 279 
that the reason of its death could be other than viral infection. The two contact chickens also 280 
died, proving transmission of the virus from vaccinated chickens. However, in order to get 281 
statistically significant results concerning virus transmission from the vaccinated to not-282 
vaccinated birds it would be necessary to use a larger group of contact birds. 283 
The H5N1 virus is highly variable and the existence of multiple antigenic and genetic 284 
variants makes the generation of a universal vaccine difficult or even impossible. A partial 285 
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solution to the problem may be a “multi-clade” DNA vaccine which should potentially protect 286 
against a broader spectrum of viruses (Zhou et al., 2012). Vaccination against avian influenza 287 
is one of the tools in the control of the disease and generation of a vaccine that elicits even 288 
partial protection can greatly help limit the spread of infections in susceptible populations. 289 
The reported DNA vaccine provides 100 and 70% protection against, respectively, a 290 
homologous and heterologous virus.and fulfills the criteria established by the World 291 
Organization for Animal Health for an efficient AI vaccine (Swayne, 2012). The major 292 
advantage of this vaccine is that it can be used as a part of a DIVA strategy since the 293 
antibodies are produced exclusively against viral hemagglutinin. Although it still needs to be 294 
optimized in order to reduce its cost, optimize the immunization schedule and/or 295 
administration route, we believe that the similar DNA vaccines can be used in future as part 296 
of prophylactic, preventive or emergency strategies in the protection of valuable flocks 297 
against H5N1. 298 
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Table 1. Influenza viruses used in this study 399 
 400 
Experiment Antigen Clade  Source 
DNA vaccine H5N1 A/swan/Poland/305-
135V08/2006 
Clade 2.2 Department of Poultry Diseases, 
National Veterinary Research 
Institute, Pulawy, Poland 
HI tests in Trials 
1-5 (broilers) 
H5N2 
A/chicken/Belgium/150/1999  
- GD Deventer, Netherlands 
Challenge 
Experiment 1 and 2 
H5N1 A/turkey/Poland/35/07 Clade 2.2 Department of Poultry Diseases, 
National Veterinary Research 
Institute, Pulawy, Poland 
Challenge 
Experiment 3 
H5N1 A/crested 
eagle/Belgium/01/2004 
Clade 1 Dr. T. van den Berg (CODA-
CERVA, Brussels, Belgium) 
HI tests in 
Experiments 1-3 
(SPF chickens)  
H5N1 A/Ck/Scotland/59 
Inactivated Antigen  
(Sc) 
Eurasian 
group 
Animal Health and Veterinary 
Laboratories Agency, Waybridge, 
UK 
 H5N1 A/turkey/Poland/35/07  
(Po) 
Clade 2.2 Department of Poultry Diseases, 
National Veterinary Research 
Institute, Pulawy, Poland 
 H5N1 A/crested 
eagle/Belgium/01/2004 
(Be) 
Clade 1 Dr. T. van den Berg (CODA-
CERVA, Brussels, Belgium) 
 401 
402 
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Table 2. Design of immunization and challenge experiments 403 
 404 
 
Experiment / route 
Group size Respective treatment day after 
hatching 
Imm Cntr Cnct Prime/Boost Blood Challenge 
Immunization 
(broilers) 
Trial 1 / sc 14 10 n/a 10/22 21/42 n/a 
Trial 2 / sc 28 14 n/a 5/19 18/40 n/a 
Trial 3 / sc, im 30 10 n/a 6/21 20/42 n/a 
Trial 4 / im 24 5 n/a 7/21 20/38 n/a 
Trial 5 / im 24 3 n/a 7/21 20/42 n/a 
Challenge  
(SPF) 
Exp 1 / im 10 3 2 7/21 21/35/42/56 42 
Exp 2 / im 5 2 1 7/21 21/35/42/63/ 
70/77 
77 
Exp 3 / im 10 5 2 7/21 21/35/42/56 42 
 405 
Routes of immunization (sc - subcutaneous; im - intramuscular). Imm - immunized; Cntr - 406 
control (non-immunized); Cnct – contact; Prime - first immunization; Boost - second 407 
immunization; Blood - blood collection; Challenge - experimental infection with H5N1 virus; 408 
n/a – non-applicable. For all experiments with experimental infection (challenge) SPF 409 
(specific pathogen free) chickens were used. 410 
 411 
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Table 3. Viral RNA detection after challenging of vaccinated chickens 412 
 413 
  Days post infection (d.p.i.) 
  3  7  10 14 
 O  
(+/t) 
C  
(+/t) 
O  
(+/t) 
C  
(+/t) 
O  
(+/t) 
C  
(+/t) 
O  
(+/t) 
C  
(+/t) 
Exp 1 Immun 1/10  
(3log10 EID50) 
0/10 0/10 0/10 0/10 0/10 1/10  
(<2 log10 EID50) 
0/10 
Contact 0/2 0/2 0/2 0/2 0/2 0/2 0/2 0/2 
Exp 2 Immun 2/5  
(<2-3.3log10 EID50) 
0/5 0/5 0/5 0/5 0/5 0/5 0/5 
Contact 0/1 0/1 1/1  
(6.2 log10 EID50) 
1/1  
(4.6log10 EID50) 
-
a
 - - - 
Exp 3 Immun 7/10  
(2.4-5.8log10 EID50) 
0/10 3/9
b
  
(3.0-5.3log10 EID50) 
1/9  
(3.3log10 EID50) 
0/9  1/9  
(<2 log10 EID50) 
0/7
c
 0/7 
Contact 2/2  
(5.3-6.9log10 EID50) 
2/2  
(6.1-7.0log10 EID50) 
-
d
 - - - - - 
 414 
Results are shown for immunized (Immun) and contact chickens. Results for corresponding control groups (non-immunized and infected) are not 415 
shown. These chickens always died by 3 dpi and had large amounts of the virus (usually > 5 log10 EID50 per ml of swab). The number of virus-416 
positive (+) and of all individuals (total, t) in each group is provided. The amount of viral RNA in shedding chickens is shown in brackets. O – 417 
oropharyngeal swabs, C – cloacal swabs; a bird died on 7 dpi, b bird died on 5 dpi, c one bird died on 10 dpi and one bird died on 13 dpi, d birds 418 
died on 3 and 4 dpi.  419 
Experimental infection (challenge) was performed on 42
nd
 (Exp 1 and Exp 3) and on 77
th
 day after hatching (Exp 2) with either virus from the 420 
homologous clade (Exp 1 and Exp 2) or virus from a heterologous clade (Exp 3). Results obtained with the H5N1 virus from the clade 421 
homologous to the one used for preparing the DNA vaccine are highlighted. 422 
 423 
 424 
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Figure Legends 
Figure 1. Chicken immune responses to DNA vaccine. Anti-HA Ab measured by ELISA (A, 
B and C) and HI of corresponding sera (C) are shown for individual chickens in each 
group. The number (n) of chicken per group is indicated; sc, subcutaneous; im, 
intramuscular; buffer - chickens received two doses of buffer; vector – chickens received 
empty vector; (-)carrier – chickens received DNA without lipid carrier; doses of DNA 
(250, 125 or 62 µg) are specified; chickens were immunized twice unless indicated 
otherwise, where 1x denotes the group which received only the first dose. In Trial 1 (A) 
either the short or long variant of the vaccine was used, while in Trials 2 (B) and Trials 3-5 
(C) only the long variant was used. 
Figure 2. Dynamics of HI titer in immunized and infected groups of chickens. Chickens in 
Experiments 1 and 2 were challenged with H5N1 from clade 2.2 (homologous to the 
vaccine), while in Experiment 3 with H5N1 from heterologous clade 1. Challenge was on 
day 42 in Experiments 1 and 3 and on day 77 in Experiment 2. Chickens from the control 
(non-immunized) groups had no detectable serological response to any of the antigens 
tested and they are not shown. Annotations on horizontal axes refer to the type of virus 
used for HI test (Sc - A/Ck/Scot/59; Po - A/turkey/Poland/35/07; Be - A/crested 
eagle/Belgium/01/2004) and to the day of blood collection. 
Figure 3. Results of challenge experiments. (A) Experiment 1 – infection with homologous 
HPAIV three weeks post boost (wpb). (B) Experiment 2 – infection with homologous 
HPAIV eight wpb. (C) Experiment 3 – infection with heterologous HPAIV three wpb. The 
data are shown as percentage survival in respective groups (Cntr – control chickens, Cnct – 
contact chickens, Imm – immunized chickens).  
Supplementary Figure 1. Statistical analysis of chicken immune responses to DNA vaccine. 
The values for individual chickens and other explanations are as in Figure 1.  
Supplementary Figure 2. Dynamics of HI titer in individual immunized and infected 
chickens. Chickens in Experiments 1 and 2 were challenged with H5N1 from clade 2.2 
(homologous to the vaccine), while in Experiment 3 with H5N1 from heterologous clade 1. 
Challenge was on day 42 in Experiments 1 and 3 and on day 77 in Experiment 2. Numbers 
on horizontal axes indicate individual chickens. Only data for chickens from immunized 
groups are shown. Chickens from the control (non-immunized) groups had no detectable 
serological response to any of the antigens tested. Asterisks indicate that the test was not 
17 
 
performed. Three birds from the immunized and challenged group in Experiment 3 died on 
days 5, 10 and 13 (birds No. 24, 23 and 25, respectively). 
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